 MONT-SAINT-GUIBERT, Belgium, April 19, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities. 